Silencing peroxiredoxin-2 sensitizes human colorectal cancer cells to ionizing radiation and oxaliplatin

• Published in: Cancer letters 2017-03, Vol.388, p.312-319
• Main Authors: Cerda, María Belén, Lloyd, Rodrigo, Batalla, Milena, Giannoni, Florencia, Casal, Mariana, Policastro, Lucia
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Cancer therapies; Cell growth; Cell Line, Tumor; Cell Proliferation; Cloning; Colorectal cancer; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Conflicts of interest; Enzymes; Female; Genomes; Hematology, Oncology and Palliative Medicine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds - pharmacology; Organoplatinum Compounds - therapeutic use; Oxaliplatin; Peroxiredoxin 2; Peroxiredoxins - metabolism; Radiation sensitivity; Radiation, Ionizing; Signal transduction
• ISSN: 0304-3835; 1872-7980
• DOI: 10.1016/j.canlet.2016.12.009

Abstract Colorectal cancer (CRC) remains one of the leading causes of cancer-related death worldwide. Antioxidant enzymes decrease the generation of ionizing radiation (IR)-induced free radicals and therefore are associate to radioresistance. The main goal of this work is to study the involvement of peroxirredoxin-2 (Prx2) in the radio and chemoradiotherapy response in CRC cells in vitro and in vivo. We found that Prx2 oxidation state is associated to differential response to ionizing radiation in CRC cell lines. HCT116 radioresistant CRC cell line have lower ROS levels and a higher monomer/dimer Prx2 ratio, compared to halfway resistant Caco-2 and T84, and radiosensitive LoVo cell line. Constitutive and transient Prx2 silencing in CRC cells increase ROS levels, and most importantly, enhance in vitro radiation sensitivity. In addition, we showed that administration of IR plus oxaliplatin in down regulated Prx2 HCT116 cells has higher citotoxic effect than in control cells. Finally, radiosensitizing effect of Prx2 depletion was confirmed in vivo . These results suggest that Prx2 is an important component in tumoral radiation response, and their inhibition could improve radio and chemoradiotherapy protocols in patients with CRC.